Continuous dopaminergic delivery in Parkinson's disease

Angelo Antonini, Giulia Ursino, Daniela Calandrella, Laura Bernardi, Mauro Plebani

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Motor fluctuations and dyskinesias occur in the majority of patients with Parkinson's disease (PD) and are likely to result from changes in dopamine production, storage and release, occurring as consequences of the nigrostriatal degenerative process. All studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. In advanced PD patients, switching from a pulsatile to continuous dopaminergic delivery may widen patients' therapeutic window. Currently, this can be accomplished only with subcutaneous apomorphine or duodenal levodopa infusions. Apomorphine is a highly soluble agonist whose effect is similar to dopamine. Conversely, replacing whole oral therapy with levodopa infusion bypasses gastric emptying and avoids peaks and troughs in plasma by releasing levodopa in the duodenum/jejunum.

Original languageEnglish
JournalJournal of Neurology
Volume257
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Levodopa
Parkinson Disease
Apomorphine
Dyskinesias
Dopamine
Gastric Emptying
Dopamine Agonists
Jejunum
Secondary Prevention
Duodenum
Therapeutics

Keywords

  • Apomorphine
  • Dopamine agonists
  • Duodenal levodopa
  • Dyskinesia
  • Infusion
  • Motor complications
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Antonini, A., Ursino, G., Calandrella, D., Bernardi, L., & Plebani, M. (2010). Continuous dopaminergic delivery in Parkinson's disease. Journal of Neurology, 257(SUPPL. 2). https://doi.org/10.1007/s00415-010-5714-1

Continuous dopaminergic delivery in Parkinson's disease. / Antonini, Angelo; Ursino, Giulia; Calandrella, Daniela; Bernardi, Laura; Plebani, Mauro.

In: Journal of Neurology, Vol. 257, No. SUPPL. 2, 11.2010.

Research output: Contribution to journalArticle

Antonini, A, Ursino, G, Calandrella, D, Bernardi, L & Plebani, M 2010, 'Continuous dopaminergic delivery in Parkinson's disease', Journal of Neurology, vol. 257, no. SUPPL. 2. https://doi.org/10.1007/s00415-010-5714-1
Antonini A, Ursino G, Calandrella D, Bernardi L, Plebani M. Continuous dopaminergic delivery in Parkinson's disease. Journal of Neurology. 2010 Nov;257(SUPPL. 2). https://doi.org/10.1007/s00415-010-5714-1
Antonini, Angelo ; Ursino, Giulia ; Calandrella, Daniela ; Bernardi, Laura ; Plebani, Mauro. / Continuous dopaminergic delivery in Parkinson's disease. In: Journal of Neurology. 2010 ; Vol. 257, No. SUPPL. 2.
@article{65605011925348babee7afc76cac0f6a,
title = "Continuous dopaminergic delivery in Parkinson's disease",
abstract = "Motor fluctuations and dyskinesias occur in the majority of patients with Parkinson's disease (PD) and are likely to result from changes in dopamine production, storage and release, occurring as consequences of the nigrostriatal degenerative process. All studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. In advanced PD patients, switching from a pulsatile to continuous dopaminergic delivery may widen patients' therapeutic window. Currently, this can be accomplished only with subcutaneous apomorphine or duodenal levodopa infusions. Apomorphine is a highly soluble agonist whose effect is similar to dopamine. Conversely, replacing whole oral therapy with levodopa infusion bypasses gastric emptying and avoids peaks and troughs in plasma by releasing levodopa in the duodenum/jejunum.",
keywords = "Apomorphine, Dopamine agonists, Duodenal levodopa, Dyskinesia, Infusion, Motor complications, Parkinson's disease",
author = "Angelo Antonini and Giulia Ursino and Daniela Calandrella and Laura Bernardi and Mauro Plebani",
year = "2010",
month = "11",
doi = "10.1007/s00415-010-5714-1",
language = "English",
volume = "257",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Continuous dopaminergic delivery in Parkinson's disease

AU - Antonini, Angelo

AU - Ursino, Giulia

AU - Calandrella, Daniela

AU - Bernardi, Laura

AU - Plebani, Mauro

PY - 2010/11

Y1 - 2010/11

N2 - Motor fluctuations and dyskinesias occur in the majority of patients with Parkinson's disease (PD) and are likely to result from changes in dopamine production, storage and release, occurring as consequences of the nigrostriatal degenerative process. All studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. In advanced PD patients, switching from a pulsatile to continuous dopaminergic delivery may widen patients' therapeutic window. Currently, this can be accomplished only with subcutaneous apomorphine or duodenal levodopa infusions. Apomorphine is a highly soluble agonist whose effect is similar to dopamine. Conversely, replacing whole oral therapy with levodopa infusion bypasses gastric emptying and avoids peaks and troughs in plasma by releasing levodopa in the duodenum/jejunum.

AB - Motor fluctuations and dyskinesias occur in the majority of patients with Parkinson's disease (PD) and are likely to result from changes in dopamine production, storage and release, occurring as consequences of the nigrostriatal degenerative process. All studies comparing levodopa versus dopamine agonist early therapy indicate that initiation with agonists is associated with a reduced risk of motor complications - in particular, dyskinesias - possibly because agonists' longer half-lives provide continuous dopaminergic delivery. In advanced PD patients, switching from a pulsatile to continuous dopaminergic delivery may widen patients' therapeutic window. Currently, this can be accomplished only with subcutaneous apomorphine or duodenal levodopa infusions. Apomorphine is a highly soluble agonist whose effect is similar to dopamine. Conversely, replacing whole oral therapy with levodopa infusion bypasses gastric emptying and avoids peaks and troughs in plasma by releasing levodopa in the duodenum/jejunum.

KW - Apomorphine

KW - Dopamine agonists

KW - Duodenal levodopa

KW - Dyskinesia

KW - Infusion

KW - Motor complications

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=80053344990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053344990&partnerID=8YFLogxK

U2 - 10.1007/s00415-010-5714-1

DO - 10.1007/s00415-010-5714-1

M3 - Article

C2 - 21080194

AN - SCOPUS:80053344990

VL - 257

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - SUPPL. 2

ER -